Cuaj-Canadian Urological Association Journal最新文献

筛选
英文 中文
Images in urology - Duplicated inferior vena cava A potential challenging anomaly for retroperitoneal surgery. 影像-重复的下腔静脉:腹膜后手术潜在的挑战性异常。
IF 1.9 4区 医学
Cuaj-Canadian Urological Association Journal Pub Date : 2024-03-01 DOI: 10.5489/cuaj.8522
Alex Ng, Annie Tsung, Christopher Nguan, David Harriman
{"title":"Images in urology - Duplicated inferior vena cava A potential challenging anomaly for retroperitoneal surgery.","authors":"Alex Ng, Annie Tsung, Christopher Nguan, David Harriman","doi":"10.5489/cuaj.8522","DOIUrl":"10.5489/cuaj.8522","url":null,"abstract":"","PeriodicalId":50613,"journal":{"name":"Cuaj-Canadian Urological Association Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10954278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138446828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case - Laparoscopic radical prostatectomy in a transgender woman after gender-affirming vaginoplasty. 病例-腹腔镜根治性前列腺切除术后变性妇女的性别确认阴道成形术。
IF 1.9 4区 医学
Cuaj-Canadian Urological Association Journal Pub Date : 2024-03-01 DOI: 10.5489/cuaj.8387
Sahil Kumar, Scott Tyldesley, Christina I Poon, James T W Saunders, Christopher C Hoag
{"title":"Case - Laparoscopic radical prostatectomy in a transgender woman after gender-affirming vaginoplasty.","authors":"Sahil Kumar, Scott Tyldesley, Christina I Poon, James T W Saunders, Christopher C Hoag","doi":"10.5489/cuaj.8387","DOIUrl":"10.5489/cuaj.8387","url":null,"abstract":"","PeriodicalId":50613,"journal":{"name":"Cuaj-Canadian Urological Association Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10954281/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138446824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of salvage radical prostatectomy vs. salvage ablation therapy for biopsy-proven radio-recurrent localized prostate cancer. 挽救性根治性前列腺切除术与挽救性消融术治疗生物梅毒放射性局限性前列腺癌症的比较。
IF 1.9 4区 医学
Cuaj-Canadian Urological Association Journal Pub Date : 2024-02-01 DOI: 10.5489/cuaj.8373
Victor McPherson, Shiva M Nair, Amy L Tin, Malcolm Dewar, Khurram Siddiqui, Daniel D Sjoberg, Andrew J Vickers, James Eastham, Joseph L Chin
{"title":"Comparison of salvage radical prostatectomy vs. salvage ablation therapy for biopsy-proven radio-recurrent localized prostate cancer.","authors":"Victor McPherson, Shiva M Nair, Amy L Tin, Malcolm Dewar, Khurram Siddiqui, Daniel D Sjoberg, Andrew J Vickers, James Eastham, Joseph L Chin","doi":"10.5489/cuaj.8373","DOIUrl":"10.5489/cuaj.8373","url":null,"abstract":"<p><strong>Introduction: </strong>Radiation therapy for prostate cancer is associated with a 15-20% five-year recurrence rate. Patients with recurrence in the prostate only are candidates for salvage local therapies; however, there is no consensus on modality. This study uses registries at Memorial Sloan Kettering Cancer Center (MSKCC) and University of Western Ontario (UWO) to compare the oncologic outcomes of salvage radical prostatectomy (SRP) and salvage ablation (SA).</p><p><strong>Methods: </strong>A total of 444 patients were available for analysis. Due to intergroup differences, propensity score methodology was used and identified 378 patients with more comparable pre-salvage prostate-specific antigen (PSA), Gleason score, and primary radiation treatment. Patients underwent SRP at MSKCC and SA at UWO.</p><p><strong>Results: </strong>Of the 378 patients, 48 died of disease, with a 6.0-year median (interquartile range [IQR] 3.0, 9.7) followup among survivors; 88 developed metastases, with a median 4.6-year (IQR 2.3, 7.9) followup among metastasis-free survivors. There was a non-significantly higher rate of cancer-specific (hazard ratio [HR ] 1.02, 95% confidence interval [CI] 0.51, 2.06, p=0.9) and improved metastasis-free survival (HR 0.71, 95% CI 0.44, 1.13, p=0.15) among patients undergoing SA compared to patients undergoing SRP. There were 143 patients who received hormonal therapy, with higher rates of androgen deprivation therapy (ADT) in SA (HR 1.42, 95% CI 0.97, 2.08, p=0.068), although this did not meet conventional levels of significance.</p><p><strong>Conclusions: </strong>This propensity score analysis of salvage therapy for radio-recurrent prostate cancer identified no statistically significant differences in oncologic outcome between SRP and SA; however, there was evidence of a lower risk of ADT in the cohort undergoing SRP. Given they are both potentially curative therapies, these treatments are viable options for men with clinically localized, radio-recurrent prostate cancer rather than ADT alone. Future research may further elucidate subpopulations that may be more amenable to either SRP or SA.</p>","PeriodicalId":50613,"journal":{"name":"Cuaj-Canadian Urological Association Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10841561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71488436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The quality of YouTube videos on radiotherapy and prostatectomy for prostate cancer. 关于癌症前列腺放射治疗和前列腺切除术的YouTube视频质量。
IF 1.9 4区 医学
Cuaj-Canadian Urological Association Journal Pub Date : 2024-02-01 DOI: 10.5489/cuaj.8523
Natalie Wong, Paris-Ann Ingledew
{"title":"The quality of YouTube videos on radiotherapy and prostatectomy for prostate cancer.","authors":"Natalie Wong, Paris-Ann Ingledew","doi":"10.5489/cuaj.8523","DOIUrl":"10.5489/cuaj.8523","url":null,"abstract":"<p><strong>Introduction: </strong>Prostate cancer ranks as the third leading cause of death among Canadian men and is primarily treated with radiotherapy and prostatectomy. Given YouTube's significant global traffic, patients often turn to it for information on treatment and side effects. This study assessed YouTube videos for prostate cancer patients, focusing on radiotherapy, prostatectomy, and side effect management.</p><p><strong>Methods: </strong>The study analyzed 50 YouTube videos, comparing their accuracy and coverage against the National Comprehensive Cancer Network (NCCN), UpToDate, and cancer.ca. Two raters were involved in the review of the videos to ensure inter-rater reliability.</p><p><strong>Results: </strong>Video lengths ranged from 1-60 minutes (mean 11 minutes) and creation dates ranged from 2012-2021. Videos were presented by physicians, patients, or allied health professionals (75%, 16%, and 8%, respectively). Results showed physician presenters had a Video Power Index (video popularity) of 23.45, while patient presenters had an average of 61.36 (almost three times as popular as physician-led videos). The overall accuracy of videos showed that 82% demonstrated completely accurate and detailed information, 18% showed partially complete information, and 76% showed no biased information. No false information was found in any videos.</p><p><strong>Conclusions: </strong>This study showed that while the YouTube informational videos included good coverage of treatment side effects, there were gaps in information regarding quality of life after treatment or management of side effects. Information from this study can benefit the provider-patient interaction, with the hope that healthcare providers create more videos on quality of life after treatment and management of side effects to satisfy patient needs.</p>","PeriodicalId":50613,"journal":{"name":"Cuaj-Canadian Urological Association Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10841556/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71488444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MV140 sublingual vaccine reduces recurrent urinary tract infection in women Results from the first North American clinical experience study. MV140舌下疫苗可减少女性复发性尿路感染:第一项北美临床经验研究的结果。
IF 1.9 4区 医学
Cuaj-Canadian Urological Association Journal Pub Date : 2024-02-01 DOI: 10.5489/cuaj.8455
J Curtis Nickel, Kerri-Lynn Kelly, Ashley Griffin, D Elterman, Janet Clark-Pereira, R Christopher Doiron
{"title":"MV140 sublingual vaccine reduces recurrent urinary tract infection in women Results from the first North American clinical experience study.","authors":"J Curtis Nickel, Kerri-Lynn Kelly, Ashley Griffin, D Elterman, Janet Clark-Pereira, R Christopher Doiron","doi":"10.5489/cuaj.8455","DOIUrl":"10.5489/cuaj.8455","url":null,"abstract":"<p><strong>Introduction: </strong>This is the first North American clinical evidence for MV140, a novel bacterial sublingual vaccine, developed for prevention of recurrent urinary tract infection (UTI) in women.</p><p><strong>Methods: </strong>Female subjects with ≥3 documented UTIs/year underwent three-month vaccination treatment, nine-month efficacy period, and optional three-month followup (total 15 months). Primary outcome was no clinically diagnosed UTI following vaccination (UTI-free rate). Secondary outcomes included absolute, mean, and median overall reduction in UTI compared to pre-vaccination, quality of life, global response assessment, patient satisfaction, microbiology, and safety.</p><p><strong>Results: </strong>Sixty-seven subjects (mean age 56 years, range 18-80) were enrolled; 64 completed the vaccination period and at least one post-vaccination assessment. Prior to vaccination, subjects reported a mean 6.8 UTIs/year. The UTI-free rate for the nine-month efficacy period was 40.6%. Compared to the infection rate in the year prior to vaccination, the reduction was 75.3% for the nine-month efficacy period post-vaccination. At 12-month followup, 80.3% reported that they were moderately/markedly improved; 58.1% were mostly satisfied, pleased, or delighted, while mean quality of life score improved by 1.5 points. Fourteen of the adverse events in nine subjects were potentially related to the vaccine - all mild and resolved by three months. None of the 13 serious adverse events were related to vaccine.</p><p><strong>Conclusions: </strong>This first-in-North-America, prospective case series with the sublingual vaccine, MV140, adds further clinical evidence to its safety and effectiveness in reducing recurrent UTIs in women.</p>","PeriodicalId":50613,"journal":{"name":"Cuaj-Canadian Urological Association Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10841562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71488445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sacral neuromodulation in the golden years: Treatment outcomes in elderly 75 years and older. 黄金年代的脊髓神经调控:75岁及以上老年人的治疗结果。
IF 1.9 4区 医学
Cuaj-Canadian Urological Association Journal Pub Date : 2024-02-01 DOI: 10.5489/cuaj.8421
Roseanne Ferreira, Samuel Otis-Chapados, Emad Alwashmi, Naeem Bhojani, Kevin C Zorn, Bilal Chughtai, Dean S Elterman
{"title":"Sacral neuromodulation in the golden years: Treatment outcomes in elderly 75 years and older.","authors":"Roseanne Ferreira, Samuel Otis-Chapados, Emad Alwashmi, Naeem Bhojani, Kevin C Zorn, Bilal Chughtai, Dean S Elterman","doi":"10.5489/cuaj.8421","DOIUrl":"10.5489/cuaj.8421","url":null,"abstract":"<p><strong>Introduction: </strong>Despite high prevalence and increased severity and burden of overactive bladder (OAB) and fecal incontinence (FI) in the elderly, sacral neuromodulation (SNM) is often overlooked as a potential treatment option for this demographic. In this study, we report the outcomes of SNM in patients aged 75 years or older at the time of surgery.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of patients who underwent SNM implantation between 2013 and 2022 performed by a single, high-volume urologist at a tertiary center. Success, complication, and adjunct therapy rates were analyzed by Fisher's or Wilcox rank-sum test as appropriate. We compared outcomes between patients aged 75-79 years and octogenarians.</p><p><strong>Results: </strong>Of 632 patients, 50 were ≥75 years. Patients had a mean age of 78.4±2.6 years and were predominantly female (84%). The indications for SNM were 66% OAB, 16% FI, 16% non-obstructive urinary retention, and 4% pelvic pain. Within the first year, 94% of patients reported satisfaction and improvement in symptoms, while 76% continued to experience improvement beyond one year. SNM insertion led to reduced oral medication use from 68% to 24% (p<0.0001). The complication rate was 16% and mostly included device pain. No significant difference was observed in treatment success, complication, or adjunct therapy rate between age groups.</p><p><strong>Conclusions: </strong>SNM is a safe and effective option in well-selected patients over the age of 75 years. Treatment success rate is comparable to younger cohorts. Advanced age should not preclude third-line therapy options in this population.</p>","PeriodicalId":50613,"journal":{"name":"Cuaj-Canadian Urological Association Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10841569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71488441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CUASF: An indispensable contributor to urologic science in Canada. 加拿大泌尿科学联合会:加拿大泌尿科学不可或缺的贡献者。
IF 1.9 4区 医学
Cuaj-Canadian Urological Association Journal Pub Date : 2024-02-01 DOI: 10.5489/cuaj.8702
Neal E Rowe, D Robert Siemens
{"title":"CUASF: An indispensable contributor to urologic science in Canada.","authors":"Neal E Rowe, D Robert Siemens","doi":"10.5489/cuaj.8702","DOIUrl":"10.5489/cuaj.8702","url":null,"abstract":"","PeriodicalId":50613,"journal":{"name":"Cuaj-Canadian Urological Association Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10841570/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139693463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Groundhog clinic. 土拨鼠诊所
IF 1.9 4区 医学
Cuaj-Canadian Urological Association Journal Pub Date : 2024-02-01 DOI: 10.5489/cuaj.8717
Michael Leveridge
{"title":"Groundhog clinic.","authors":"Michael Leveridge","doi":"10.5489/cuaj.8717","DOIUrl":"10.5489/cuaj.8717","url":null,"abstract":"","PeriodicalId":50613,"journal":{"name":"Cuaj-Canadian Urological Association Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10841555/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139693465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can salvage radical prostatectomy and salvage ablation achieve similar outcomes in radio-recurrent localized prostate cancer? 挽救性前列腺癌根治术和挽救性消融术对放射复发的局部前列腺癌能否取得相似的疗效?
IF 1.9 4区 医学
Cuaj-Canadian Urological Association Journal Pub Date : 2024-02-01 DOI: 10.5489/cuaj.8700
Patrick Albers, Adam Kinnaird
{"title":"Can salvage radical prostatectomy and salvage ablation achieve similar outcomes in radio-recurrent localized prostate cancer?","authors":"Patrick Albers, Adam Kinnaird","doi":"10.5489/cuaj.8700","DOIUrl":"10.5489/cuaj.8700","url":null,"abstract":"","PeriodicalId":50613,"journal":{"name":"Cuaj-Canadian Urological Association Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10841559/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139693462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dr. Thomas Eid 1933-2023. 托马斯-艾德博士 1933-2023年
IF 1.9 4区 医学
Cuaj-Canadian Urological Association Journal Pub Date : 2024-02-01 DOI: 10.5489/cuaj.8718
Thomas Eid
{"title":"Dr. Thomas Eid 1933-2023.","authors":"Thomas Eid","doi":"10.5489/cuaj.8718","DOIUrl":"10.5489/cuaj.8718","url":null,"abstract":"","PeriodicalId":50613,"journal":{"name":"Cuaj-Canadian Urological Association Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10841560/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139693464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信